HC Wainwright & Co. Reiterates Buy on Vera Therapeutics, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce reiterated a Buy rating on Vera Therapeutics (NASDAQ:VERA) and maintained a $10 price target.
June 08, 2023 | 10:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce reiterated a Buy rating on Vera Therapeutics and maintained a $10 price target.
The reiteration of a Buy rating and maintenance of a $10 price target by HC Wainwright & Co. analyst Ed Arce indicates a positive outlook for Vera Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100